# Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

> **NCT00915733** · PHASE4 · COMPLETED · sponsor: **Gyeongsang National University Hospital** · enrollment: 80 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** cilostazol
- **DRUG:** clopidogrel (Plavix)
- **GENETIC:** CYP2C19
- **DRUG:** aspirin (Acetylsalicylic acid)

## Key facts

- **NCT ID:** NCT00915733
- **Lead sponsor:** Gyeongsang National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2009-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915733, "Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00915733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*